Improving Outcomes in Non–24-Hour Sleep-Wake DisorderIdentifying Patients and Tailoring Therapy
Non-24-hour disorder in blind individuals revisited: variability and the influence of environmental time cues.
Emens JS, et al. Sleep. 2013;36(7):1091-1100
Garbazza C, et al. Front Neurol. 2016:7:17.
Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D, et al. Expert Opin Drug Saf. 2015;14(11):1673-1685.
Alertness, mood, and performance rhythm disturbances associated with circadian sleep disorders in the blind.
Lockley SW, et al. J. Sleep. Res. 2008;17(2):207-216.
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW, et al. Lancet. 2015;386(10005):1754-1764.
Luyster FS, et al. Sleep. 2012;35(6):727-734.
Personality differences in delayed sleep-wake phase disorder and non-24-hour sleep-wake rhythm disorder patients relative to healthy sleepers.
Micic G, et al. Sleep Med. 2016 Jun 16. [Epub ahead of print].
Roth T, et al. Curr Med Res Opin. 2010;26(suppl 2):S3-S24.
Scheer FA, et al. Proc Natl Acad Sci U S A. 2009;106(11):4453-4458.
Caffeine does not entrain the circadian clock but improves daytime alertness in blind patients with non-24-hour rhythms.
St Hilaire MA, Lockley SW. Sleep Med. 2015;16(6):800-804
Zee PC, et al. Continuum (Minneap Minn). 2013;19(1 Sleep Disorders):132-147.
Improving Outcomes in Non–24-Hour Sleep-Wake Disorder
Karl Doghramji, MD; Paul P. Doghramji, MD, FAAFP
Identifying Patients and Tailoring Therapy
A Case-Based Discussion on Diagnosis and Treatment
Practical Diagnostic and Tailored Treatment Strategies
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Improving Patient Outcomes Through Shared Clinical Decision Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors